"Potentially including lowering prices in China and an AG in the U.S." Let's get approved for CVRR in China, and hopefully the floodgates will open. Corruption in the U.S. has negated the commercialization, use and benefit of one of the cheapest, safest and most efficacious CVD drugs, per clinical trial results. Sad to expect the benefit not accruing to U.S. population, but happy to serve the rest of the world. Denner will make it happen.
News 
Market Data 
Discover 
